The global microsclerotherapy treatment market was valued at around US$ 7.0 Billion at the end of 2021. The market is projected to register a 3.4% CAGR and top a valuation of US$ 9.8 Billion by 2032.
The increasing prevalence of spider veins & varicose veins and the growing geriatric population worldwide are the variables predicted to encourage the microsclerotherapy treatment market.
Telangiectasia, a disorder where damaged blood vessels close to the surface or mucous membrane appear as pink or red lines on the skin's surface, is treated using microsclerotherapy. Telangiectasia is influenced by both genetic and environmental factors such as overexposure to sunlight and varicose vein.
Microneedles are used in microsclerotherapy treatment to inject a substance called a sclerosant. The technique involves injecting sclerosant into the afflicted veins, which kills the endothelium and causes thrombosis, fibrosis, and vascular closure. Microsclerotherapy makes use of sclerosants such as polidocanol, tetradecyl sulfate, hypertonic saline solution, and chromated glycerin.
| Attributes | Details |
| Microsclerotherapy Treatment Market Value in 2021 | US$ 7.0 Billion |
| Microsclerotherapy Treatment Market Value in 2032 | US$ 9.8 Billion |
| Microsclerotherapy Treatment Market CAGR (2022 to 2032) | 3.4% |
The rising incidence of spider and varicose veins is one of the primary reasons behind the growth of the worldwide microsclerotherapy treatment market. The treatment's relative absence of discomfort, low invasion, high efficiency, reduced postoperative complications, and the simple painkillers required during the process will be the main drivers of the development of the global industry over the projected period.
Another factor that can have a positive effect on the global market is an increase in the number of elderly people, as spider veins are more prevalent in the elderly due to weakened immune systems. The likelihood of having a chronic venous illness of the legs might well be raised by hereditary, and overweight which will ultimately create a high demand for microsclerotherapy treatment. The market for microsclerotherapy treatments will ultimately be driven by skin lesions, skin pigmentation, chronic edema, dermatitis, eczema, and ulcers caused by long-term varicose veins and thrombosis.
North America held the largest share in the global microsclerotherapy treatment market owing to the high population suffering from varicose veins, and the minimally invasive nature of the treatment.
The European market is also anticipated to grow at a rapid pace, owing to the presence of well-established players in the region.
Furthermore, the Asia Pacific region is also expected to uplift the revenue of the microsclerotherapy treatment market due to the wide availability of skilled professionals in the sclerotherapy treatment market.
Surgimedix, Inc., Merz Pharma GmbH & Co. KGaA, QOL Medical LLC, McKesson Corporation, Kreussler, Inc., Provensis, ltd, STD Pharmaceuticals Product Ltd., Medtronic plc, Teleflex Incorporated, Boston Scientific Corporation.
| Report Attributes | Details |
| Growth Rate | CAGR of 3.4% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered |
|
| Region Covered |
|
| Key Countries Profiled |
|
| Key Players |
|
| Customization | Available Upon Request |
The global microsclerotherapy treatment market is anticipated to register a CAGR of 3.4% during the forecast period.
Surgimedix, Inc., Merz Pharma GmbH & Co. KGaA, QOL Medical LLC, McKesson Corporation, Kreussler, Inc., Provensis, ltd, STD Pharmaceuticals Product Ltd., Medtronic plc, Teleflex Incorporated, Boston Scientific Corporation among others are some prominent medical device technologies market players.
Explore Similar Insights
Microsclerotherapy Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
